Senescent tumor cells exhibit intrinsically enhanced immunogenicity and can spontaneously generate tumor neoantigens. This endows their cell membrane with considerable potential as a versatile drug delivery platform and a reservoir of tumor-specific antigens for cancer immunotherapy and vaccine development. To explore the immune potential of senescent tumor cells, 4T1 breast cancer cells were subjected to a senescence inducer, doxorubicin to establish a stable senescent model. To systematically dissect the functional disparities between tumor cell membrane and senescent tumor cell membrane, label-free quantitative membrane proteomic analysis was performed on these two types of membrane vesicles.